Core Viewpoint - The article discusses the challenges and advancements in the preclinical evaluation of drugs targeting Th2-type immune response diseases, specifically atopic dermatitis and asthma, highlighting the need for improved animal models and evaluation systems [1][2]. Group 1: Disease Mechanisms and Challenges - Atopic dermatitis and asthma are chronic inflammatory diseases driven by abnormal Th2 immune responses, involving pathways such as IL-4, IL-13, and IL-5, as well as epidermal barrier dysfunction and neuroimmune dysregulation [1]. - Despite the clinical application of targeted biologics improving patient outcomes, issues such as individual response variability, acquired resistance, and long-term safety remain unresolved [1]. Group 2: Preclinical Research Dilemmas - Key questions in preclinical research include how to establish more accurate animal models that simulate skin barrier defects in atopic dermatitis and airway hyperreactivity in asthma [1]. - There is a need to optimize the drug efficacy evaluation system for Th2 immune responses to enhance clinical translation rates [1]. - New technologies are required to overcome existing model limitations in simulating neuroimmune interactions [1]. - Personalized preclinical evaluation plans must be designed for candidate drugs with different mechanisms of action [1]. Group 3: Online Course Information - An online course titled "Preclinical Drug Evaluation Models for Th2 Immune Response Diseases: Aiding New Drug Development for Atopic Dermatitis and Asthma" will delve into these topics [2]. - Participants will learn about the latest research advancements in Th2 immune diseases, methods for constructing clinically relevant animal models, and key challenges in developing innovative mouse models [2]. - The course will also cover technical solutions and case studies related to autoimmune disease efficacy platforms, along with an interactive Q&A session with the lecturer [2]. Group 4: Instructor Background - Dr. Yu Jing, a senior scientist in the pharmacodynamics research department at Saiye Bio, specializes in the development of animal models for immune reconstruction, tumor models, metabolic diseases, and autoimmune diseases, with extensive experience in efficacy validation [7]. Group 5: Efficacy Evaluation Platform - Saiye Bio offers a stable efficacy evaluation platform for autoimmune and inflammatory diseases, providing comprehensive pharmacodynamic evaluation and mechanism research services [12]. - The platform includes various models such as induced models, gene editing, and humanized models, focusing on physiological and biochemical indicators, pathological analysis, and immune cell function assessment [9][12].